Temporal dynamics and stoichiometry in human Notch signaling from Notch synaptic complex formation to nuclear entry of the Notch intracellular domain.
Delta
Notch
development
receptor
regulated proteolysis
signal transduction
signaling dynamics
synapses
transcription
transendocytosis
Journal
Developmental cell
ISSN: 1878-1551
Titre abrégé: Dev Cell
Pays: United States
ID NLM: 101120028
Informations de publication
Date de publication:
29 Mar 2024
29 Mar 2024
Historique:
received:
05
10
2023
revised:
10
01
2024
accepted:
11
03
2024
medline:
5
4
2024
pubmed:
5
4
2024
entrez:
4
4
2024
Statut:
aheadofprint
Résumé
Mammalian Notch signaling occurs when the binding of Delta or Jagged to Notch stimulates the proteolytic release of the Notch intracellular domain (NICD), which enters the nucleus to control target gene expression. To determine the temporal dynamics of events associated with Notch signaling under native conditions, we fluorescently tagged Notch and Delta at their endogenous genomic loci and visualized them upon pairing of receiver (Notch) and sender (Delta) cells as a function of time after cell contact. At contact sites, Notch and Delta immediately accumulated at 1:1 stoichiometry in synapses, which resolved by 15-20 min after contact. Synapse formation preceded the entrance of the Notch extracellular domain into the sender cell and accumulation of NICD in the nucleus of the receiver cell, which approached a maximum after ∼45 min and was prevented by chemical and genetic inhibitors of signaling. These findings directly link Notch-Delta synapse dynamics to NICD production with spatiotemporal precision.
Identifiants
pubmed: 38574735
pii: S1534-5807(24)00189-8
doi: 10.1016/j.devcel.2024.03.021
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests S.C.B. is on the board for the Institute for Protein Innovation and the Revson Foundation, on the SAB for MPM Capital and Erasca, and consults for Scorpion Therapeutics and Odyssey Therapeutics- on unrelated projects. T.K. is a member of the Medical Advisory Board of AI Therapeutics. J.C.A. is a consultant for Ayala Pharmaceuticals, Cellestia, SpringWorks, and Remix Therapeutics.